function doTooltip(e, msg) {
  if ( typeof Tooltip == "undefined" || !Tooltip.ready ) return;
  Tooltip.show(e, msg);
}

function hideTip() {
  if ( typeof Tooltip == "undefined" || !Tooltip.ready ) return;
  Tooltip.hide();
}

var ref1 = '1. Zithromax<sup>&reg;</sup> (azithromycin) full prescribing information.';
var ref2 = '2. Clarebout G, Leclercq R. Fluorescence assay for studying the ability of macrolides to induce production of ribosomal methylase. Antimicrob Agents Chemother. 2002;46:2269-2272. ';
var ref3 = '3. Poehlsgaard J, Douthwaite S. The macrolide binding site on the bacterial ribosome. Curr Drug Targets Infect Disord. 2002;2:67-78.';
var ref4 = '4. Odenholt I, Löwdin E, Cars O. Pharmacodynamics of telithromycin <em>in vitro</em> against respiratory tract pathogens. Antimicrob Agents Chemother. 2001;45:23-29.';
var ref5 = '5. Khair OA, Andrews JM, HoneyBourne D, Jevons, G, Vacheron F, Wise R.  Lung concentrations of telithromycin after oral dosing. J Antimicrob Chemother. 2001;47:837-840.';
var ref6 = '6. Data on file. sanofi-aventis U.S., Bridgewater, NJ.';

/*
var ref1 = '1. Data on file. Sanofi-Aventis Pharmaceuticals, a member of the sanofi-aventis Group. Bridgewater, NJ.';
var ref2 = '2. Appelbaum PC. Resistance among <span class="italics">Streptococcus pneumoniae</span>: implications for drug selection. Clin Infect Dis. 2002;34:1613-1620.';
var ref3 = '3. Food & Drug Administration. Label and Approval Histories for Augmentin, Zithromax, and Biaxin. Available at: http://www.FDA.gov. Accessed April 4, 2005.';
var ref4 = '4. Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med. 1995;99(suppl 6B):3S-7S.';
var ref5 = '5. Livermore DM. Antibiotic resistance in staphylococci. Int J Antimicrob Agents. 2000;16 (suppl 1):S3-S10.';
var ref6 = '6. Lerner PL. Producing penicillin. N Engl J Med. 2004;351:524.';
var ref2 = '2. Zithromax&#174; (azithromycin) full prescribing information, Biaxin&#174; (clarithromycin) full prescribing information, AugmentinTM (amoxicillin/clavulanate) full prescribing information, Ceftin&#174; (cefuroxime axetil) full prescribing information, Cefzil&#174; (cefprozil) full prescribing information, Levaquin&#174; (levofloxacin) full prescribing information, Avelox&#174; (moxifloxacin) full prescribing information, Tequin&#174; (gatifloxacin) full prescribing information, and Factive&#174; (gemifloxacin) full prescribing information. Physicians\' Desk Reference&#174;. 59th ed. Montvale, NJ: Medical Economics Company, Inc.; 2005.';
var ref3 = '3. Clarebout G, Leclercq R. Fluorescence assay for studying the ability of macrolides to induce production of ribosomal methylase. Antimicrob Agents Chemother. 2002;46:2269-2272. ';
var ref9 = '9. Alexander Project. MIC statistics from the Alexander Project, United States 1992–1999. Available at: http://www.alexandernetwork.com. Accessed May 11, 2005.';
var ref10 = '10. Zhanel GG, Johanssen C, Noreddin A, et al. Pharmacodynamic modeling of telithromycin and azithromycin vs. genotypically characterized (mefA and ermB) macrolide resistant strains of <span class="italics">Streptococcus pneumoniae</span> simulating free serum and free epithelial lining fluid concentrations. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); October 30–November 2, 2004; Washington, DC.';
var ref11 = '11. Buchanan PP, Stephens TA, Leroy B. A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis. Am J Rhinol. 2003;17:369-377.';
var ref12 = '12. Aubier M, Aldons PM, Leak A, et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med. 2002;96:862-871.';
var ref13 = '13. Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA. The Sanford Guide to Antimicrobial Therapy 2005. 35th ed. Hyde Park, Vt: Antimicrobial Therapy Inc.; 2005.';
var ref5 = '5. Poehlsgaard J, Douthwaite S. The macrolide binding site on the bacterial ribosome. Curr Drug Targets Infect Disord. 2002;2:67-78.';
var ref4 = '4. Khair';
var ref15 = '15. Zervos MJ, Heyder AM, Leroy B. Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis. J Int Med Res. 2003;31:157-169.';
var ref16 = '16. Luterman M, Tellier G, Lasko B, Leroy B. Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis. Ear Nose Throat J. 2003;82:576-590.';
var ref17 = '17. Roos K, Brunswig-Pitschner C, Kostrica R, et al. Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis. Chemotherapy. 2002;48:100-108.';
var ref18 = '18. Hagberg L, Torres A, van Rensberg D, Leroy B, Rangaraju M, Ruuth E. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection. 2002;6:378-386.';
var ref19 = '19. Klossek JM, Serrano E, Peynegre R, et al. Penetration of telithromycin (HMR 3647), a new ketolide, into sinus tissue in patients undergoing sinusectomy. Abstract presented at: 22e R&#233;union Interdisciplinaire de Chimioth&#233;rapie Anti-Infectieuse (RICAI); December 5–6, 2002; Paris, France. ';
var ref20 = '20. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; fourteenth information supplement. Vol. 24, No.1. Wayne, PA: NCCLS; 2004. Publication M100-S14 (replaces M100-S13).';
var ref6 = '6. Red Book 2005 Drug Topics. Montvale, NJ: Medical Economics Company Inc.; 2005.';
var ref6 = '6. Odenholt I, Löwdin E, Cars O. Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens. Antimicrob Agents Chemother. 2001;45:23-29. ';
var ref22 = '22. Odenholt I, L&#246;wdin E, Cars O. Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens. Antimicrob Agents Chemother. 2001;45:23-29. ';*/

var potential_ast = '* erm<sub>B</sub> resistance';
var potential_cross = '&#134;The clinical significance of induction of resistance is unknown';
var potential_double_cross = '&#134;&#134;From a study using fluorescence induction assays to test the resistance-inducing capacity of macrolide antibiotics.8 8. Clarebout G, Leclercq R. Fluorescence assay for studying the ability of macrolides to induce production of ribosomal methylase. Antimicrob Agents Chemother. 2002;46:2269-2272.';
var how_ast = '*KETEK&#174; is indicated for MDRSP in mild to moderate CAP.';
var how_double_ast = '*The clinical significance of <em>in vitro</em> activity is unknown';
var efficacy_ast = '*KETEK&#174; is recommended for severe AECB and as a primary therapy for ABS in penicillin-allergic patients.';
var efficacy_cross = '&#134;Based on test-of-cure visit, 17 to 24 days after initial indication of therapy with KETEK&#174 or amoxicillin.';
var efficacy_double_cross = '&#134;&#134;Based on test-of-cure visit, 17 to 24 days after initial indication of therapy with KETEK&#174 or cefuroxime.';
var work_cross = '&#134;Tissue concentration by weight measured at 2 hours post-dose.';
var tispen_ast = '*<em>In Vitro</em> Activity and Tissue Penetration Does Not Imply Clinical Effectiveness';
var newast = "*Tissue Penetration does not imply clinical effectiveness. The clinical significance of <em>in vitro</em> activity is unknown"